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Abstract 
Background: [68 Ga]Ga-DOTATATE PET/CT is now recognised as the most sensitive functional imaging modality for 
the diagnosis of well-differentiated neuroendocrine tumours (NET) and can inform treatment with peptide receptor 
radionuclide therapy with  [177Lu]Lu-DOTATATE. However, somatostatin receptor (SSTR) expression is not unique to 
NET, and therefore,  [68 Ga]Ga-DOTATATE PET/CT may have oncological application in other tumours. Molecular profil-
ing of gastrointestinal stromal tumours that lack activating somatic mutations in KIT or PDGFRA or so-called ‘wild-type’ 
GIST (wtGIST) has demonstrated that wtGIST and NET have overlapping molecular features and has encouraged 
exploration of shared therapeutic targets, due to a lack of effective therapies currently available for metastatic wtGIST.
Aims: To investigate (i) the diagnostic role of  [68 Ga]Ga-DOTATATE PET/CT; and, (ii) to investigate the potential of this 
imaging modality to guide treatment with  [177Lu]Lu-DOTATATE in patients with wtGIST.
Methods: [68 Ga]Ga-DOTATATE PET/CT was performed on 11 patients with confirmed or metastatic wtGIST and one 
patient with a history of wtGIST and a mediastinal mass suspicious for metastatic wtGIST, who was subsequently 
diagnosed with a metachronous mediastinal paraganglioma. Tumour expression of somatostatin receptor subtype 
2 (SSTR2) using immunohistochemistry was performed on 54 tumour samples including samples from 8/12 (66.6%) 
patients who took part in the imaging study and 46 tumour samples from individuals not included in the imaging 
study.
Results: [68 Ga]Ga-DOTATATE PET/CT imaging was negative, demonstrating that liver metastases had lower uptake 
than background liver for nine cases (9/12 cases, 75%) and heterogeneous uptake of somatostatin tracer was noted 
for two cases (16.6%) of wtGIST. However,  [68 Ga]Ga-DOTATATE PET/CT demonstrated intense tracer uptake in a syn-
chronous paraganglioma in one case and a metachronous paraganglioma in another case with wtGIST.
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Introduction
Gastrointestinal stromal tumours (GIST) are the most 
common mesenchymal tumours of the gastrointestinal 
tract, and the majority of adult onset GIST, so-called 
‘tyrosine kinase mutant’ GIST (TK-mutant GIST), are 
driven by activating somatic mutations in the KIT [1] 
or PDGFRA [2] genes. Wild-type GIST (wtGIST) refers 
to tumours that are negative for KIT and PDGFRA gene 
mutations and account for 15% of adult and 85% of pae-
diatric GIST [3]. wtGIST can be further classified based 
on the functional status of tumoral succinate dehydroge-
nase enzyme, as determined by the loss or preservation 
of SDHB protein expression, following immunohisto-
chemical analysis, as a surrogate marker for a deficient or 
competent SDH complex [4]. Succinate dehydrogenase 
competent (cSDH) wtGIST may be associated with an 
inherited tumour syndrome such as neurofibromatosis 
type 1 (NF1) [5], or occur sporadically due to somatic 
mutations in several genes [6, 7] or gene fusion muta-
tions [8]. SDH deficient (dSDH) wtGIST is the most 
common subcategory of wtGIST [9], and these tumours 
are driven by inherited germline mutations in one of the 
SDHx genes (SDHA/B/C/D) [9] or can occur sporadically 
following epigenetic silencing of the SDHC gene [10]. 
Patients with dSDH wtGIST are at risk of developing 
multiple tumour types including phaeochromocytoma/
paraganglioma (PPGL) and pulmonary chondroma [10]. 
Rarely, renal cell carcinoma [11] and pituitary tumours 
[12] can also develop in patients with germline SDHx 
gene mutations. Molecular profiling of wtGIST has 
revealed that these tumours share common molecular 
features with PPGL and other neuroendocrine tumours 
[13], raising the possibility that established diagnos-
tic tests and therapeutic targets utilised in the clinical 
management of neuroendocrine tumours, may also have 
application in the management of wtGIST. Furthermore, 
the indolent progressive nature of wtGIST is clinically 
reminiscent of the neuroendocrine tumour phenotype.
While clinical behaviour of wtGIST is generally indo-
lent, there are no effective treatments for patients with 
more aggressive progressing disease. Management of 
TK-mutant GIST has been greatly improved by the 
introduction of the tyrosine kinase inhibitor imatinib 
which provides an effective standard of care treatment 
in this setting [14]. Unfortunately, this treatment is inef-
fective in wtGIST since disease is not driven by tyrosine 
kinase activity [9]. The availability of a viable theranostic 
pathway in these tumours would be welcome in this area 
of unmet clinical need and is being actively explored.
Previous studies have reported high-level expression 
of the somatostatin receptor 2 (SSTR2) subtype in GIST 
tumours with unknown mutational status [15] and that 
GIST tumour sites can be identified with 111In-Octre-
otide scintigraphy in 3/6 cases [16]. Recent case reports 
evaluating genetically profiled tumours indicate that 
high SSTR2 receptor overexpression can be found in 
KIT mutant GIST [17] as well as in dSDH wtGIST [18]. 
Somatostatin receptor (SSTR) PET/CT has an estab-
lished role in the localisation of neuroendocrine tumours 
which highly express SSTR as well as a theranostic role in 
selecting patients for peptide receptor radionuclide ther-
apy (PRRT) with  [177Lu]Lu-DOTATATE [19, 20]. Therapy 
with  [177Lu]Lu-DOTATATE is highly effective in con-
trolling symptoms and progression of disease in patients 
with gastroenteropancreatic neuroendocrine tumours 
and is now approved in many health systems [20].  [68 Ga]
Ga-DOTATATE PET/CT has emerged as a highly sen-
sitive hybrid SSTR imaging modality for NET as well as 
for imaging and characterising other tumours with high 
expression of SSTR such as PPGL [21, 22] and certain 
mesenchymal tumours [23].
Based on this information, it is possible that SSTR 
PET/CT may be relevant in the clinical management of 
patients with wtGIST. This study aims to investigate the 
diagnostic role of  [68  Ga]Ga-DOTATATE PET/CT in 
patients with wtGIST and to assess the potential for ther-




Patients were recruited from the National Paediatric 
and Adult wild-type GIST (PAWS GIST UK), and clini-
cal genetics clinic at Cambridge University Hospital NHS 
Foundation Trust. Details of clinical phenotype, fam-
ily history and germline molecular testing results were 
collated from patient records. All participants provided 
written informed consent. The study was approved by the 
East of England South Cambridge Research Ethics Com-
mittee (REC ID 14/EE/1059).
[68 Ga]Ga‑DOTATATE PET/CT imaging
Patients were administered 250 (± 10%) MBq of  [68 Ga]
Ga-DOTATATE. Scanning was started after urinary 
Conclusions: Our data suggest that SSTR2 is not a diagnostic or therapeutic target in wtGIST.  [68 Ga]Ga-DOTATATE 
PET/CT may have specific diagnostic utility in differentiating wtGIST from other primary tumours such as paragan-
glioma in patients with sporadic and hereditary forms of wtGIST.
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bladder emptying and 60 min after radiopharmaceutical 
injection on a General Electric Discovery 690 scanner 
(GE Healthcare, Milwaukee, WI, USA), using 4 min per 
bed position and low dose CT for attenuation correction 
and localisation. The ordered subsets expectation maxi-
misation (OSEM) algorithm (2 interations, 24 subsets) 
was used to reconstruct the emission images with time-
of-flight modelling. Emission data were corrected for 
decay, dead time and random coincidences and normal-
ised for injected dose and patient body weight. Studies 
were viewed on a Xeleris 4 (GE) workstation for clinical 
review, and region of interest analysis was performed for 
quantitative assessment. Maximum standardised uptake 
values (SUVmax) were recorded for tumour lesions as 
well as for normal liver. Lesion to liver uptake ratios was 
calculated for each case. Lesions with an uptake ratio < 1 
were considered to have low/no receptor expression, a 
ratio of 1–2 was considered equivocal, and a ratio > 2 
was defined as representing high receptor expression 
[24]]. All imaging studies were reviewed by experienced 
nuclear medicine physicians (LA, IM, JB, IH, HC).  [68 Ga]
Ga-DOTATATE PET/CT was performed on twelve 
patients with wtGIST. DOTATATE measurements were 
performed on lesions showing solid features on standard 
of care imaging and/or the registration CT of the  [68 Ga]
Ga-DOTATATE PET/CT which were at least 2  cm or 
greater in diameter.
Immunohistochemistry
SSTR2 immunohistochemistry (IHC) was performed on 
2 µm sections of paraffin embedded tumour tissue using 
a rabbit monoclonal anti-SSTR2 antibody (Abcam, cata-
logue number ab134152) at a dilution of 1:600. Neuroen-
docrine cells in gastric mucosa, normal adrenal tissue and 
a well-differentiated pancreatic neuroendocrine tumour 
were used as a positive control for SSTR2. Adjacent nor-
mal tissue was used as an internal positive control. All 
IHC results were reviewed by an experienced pathologist 
(OG) and reported using the following scoring system: 
0 = no membranous staining; 1 =  < 25% of cells show 
membranous staining; 2 =  > 25% of cells show membra-
nous staining; 3 =  > 75% of cells show membranous stain-
ing. Data outlining GIST-specific immunohistochemistry 
markers for the 11 GIST cases included in the imaging 
study are provided in Additional file 1:  Table 1.
Germline and tumour genetic sequencing
Clinical germline DNA sequencing
DNA was extracted from peripheral blood sam-
ples according to standard protocols. Next genera-
tion sequencing of a clinical gene panel that included 
SDHA, SDHB, SDHC, SDHD, KIT PDGFRA and NF1 
was performed at Cambridge University Hospital NHS 
Foundation Trust using the TrusightOne sequenc-
ing panel (Illumina Inc., UK). An average coverage 
depth of > 20 fold was achieved for 98% of the regions 
sequenced. Sanger sequencing confirmed all detected 
variants. Multiple ligation probe analysis (MLPA) was 
performed for SDHB, SDHC and SDHD.
SDHC epimutation analysis
This was performed on DNA extracted from paraffin 
embedded tumour tissue and adjacent normal tissue 
using a pyrosequencing method previously described 
[10].
Standard of care imaging
Standard of care imaging was reviewed alongside the 
 [68  Ga]Ga-DOTATATE PET/CT for each patient. Eight 
patients had CT imaging (for two this was the registra-
tion CT of the  [68  Ga]Ga-DOTATATE PET/CT), three 
patients had MRI, and one patient had CT and MRI at 
the time of the  [68  Ga]Ga-DOTATATE PET/CT study. 
Six patients also had  [18F]FDG PET/CT studies for 
comparison.
Statistical analysis
Statistical analysis was performed using MedCalc (ver-
sion 18.2.1). A mean and standard deviation was calcu-
lated for all continuous variables. An unpaired student 
t test was employed to investigate differences between 
groups.
Results
Genotype and clinical phenotype of [68 Ga]Ga‑DOTATATE 
PET/CT imaging patient cohort
Eleven patients with a diagnosis of metastatic wtGIST 
and one patient with a mediastinal mass and suspected 
metastatic wtGIST (case 012) were recruited for  [68 Ga]
Ga-DOTATATE PET/CT imaging (Table  1). The mean 
age at diagnosis was 39  years (range 15–73  years). The 
liver was the most common site for tumour metastases, 
which were present in 11/12 patients (92%). One patient 
(case 002) had a confirmed synchronous carotid paragan-
glioma. Ten patients had a history of dSDH wtGIST, and 
two patients had cSDH wtGIST. Five patients (41.6%) had 
a pathogenic germline SDHx variant, one patient had a 
variant of uncertain significance in the SDHA gene, and 
two patients had a confirmed SDHC epimutation. One 
patient had a dSDH wtGIST but no identifiable germline 
variant and insufficient tissue available for SDHC meth-
ylation analysis (case 008) (Table 1).
Ex vivo analysis of SSTR2 expression
Tumour tissue for SSTR2 IHC was performed on 54 
tumour samples and this included tumour samples from 
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8/12 (66.6%) patients who had  [68  Ga]Ga-DOTATATE 
PET/CT imaging and 47 tumour samples from individu-
als who did not have  [68  Ga]Ga-DOTATATE PET/CT 
imaging.
SSTR2 immunohistochemistry was performed on 
tumour samples from eight of the patients who under-
went  [68  Ga]Ga-DOTATATE PET/CT (patient 002, 003, 
004, 005, 006, 007, 009 and 010). Single isolated tumour 
cells showed immunoreactivity in patient 009 (score 1); 
faint membranous staining (score 1) was seen in patients 
005 and 007. Tumours from patients 002, 004, 003, 006 
and 010 were negative for SSTR2 and were assigned 
a score of 0 (Table  2). Of note, a moderate cytoplasmic 
staining, which we interpreted as non-specific as not 
located on the exterior cellular membrane (Fig. 1 b), was 
observed in patient 006.
The 46 tumour samples from individuals who did not 
have  [68  Ga]Ga-DOTATATE PET/CT imaging included; 
14 dSDH wtGIST, 9 cSDH wtGIST and 23 TK-mutant 
GIST. The mean SSTR2 expression score was 0.73 for the 
Table 1 Clinical and molecular features of  [68 Ga]Ga-DOTATATE PET/CT imaging cohort
NA = not available
Case Sex Age Primary tumour site Metastases SDH status Germline mutation Tumour epi-mutation Other tumours
001 F 21 Gastric Liver nodal peritoneal dSDH No SDHC epimutation No
002 M 37 Gastric Liver, peritoneal dSDH SDHB c.137G > A, 
p.(Arg46Gln)
No Carotid PGL
003 F 31 Gastric Liver, peritoneal dSDH SDHA (c.1909 2A > G) No No
004 M 39 Gastric Liver, peritoneal dSDH No No No
005 F 15 Gastric Liver, peritoneal dSDH SDHA c.91C > T 
p.(Arg31Ter)
Yes No
006 M 68 Gastric Liver dSDH SDHD c.296delT 
p.(Leu99fs)
No No
007 M 21 Gastric Liver dSDH SDHA c.91C > T 
p.(Arg31Ter)
No No
008 F 33 Gastric Liver dSDH No NA No
009 M 73 Gastric Liver nodal dSDH Variant of uncertain signifi-
cance in SDHA
No No
010 M 60 Small bowel Liver cSDH No No No
011 M 63 Small bowel Liver cSDH No No No
012 F 15 Gastric Mediastinal mass dSDH No SDHC epimutation Mediastinal mass
Table 2 [68 Ga]Ga-DOTATATE PET/CT scan and IHC findings
NA = not available
Case SUVmax of most avid 
lesion
Location Clinical report Lesion to liver ratio SSTR2 IH score
001 3 Liver Negative  < 1 NA
002 13 Liver Equivocal (GIST lesion) 2 0
60 Carotid PGL Positive (PGL)  > 2.5 (9.6) NA
003 10 Liver Equivocal 1.5 0
004 2 Liver Negative  < 1 0
005 3 Liver Negative  < 1 1
006 12 Liver Negative  < 1 0
007 4 Liver Negative  < 1 1
008 4 Liver Negative  < 1 NA
009 10 Liver, nodal Negative  < 1 1
010 2.5 Liver Negative  < 1 0
011 2.8 Liver Negative  < 1 NA
012 45 Mediastinal mass Positive  > 2.5 [9] NA
40 Mediastinal node Positive  > 2.5 [8]
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dSDH wtGIST (8/14 had a score of 0, 3/14 had a score of 
1, one case had a score of 2 and two cases had a score of 
3) versus 0.22 in the cSDH wtGIST (7/9 had a score of 0 
and 2/9 had a score of 1) and 0.22 in the TK-mutant GIST 
(19/23 had a score of 0, 3/23 had a score of 1 and one case 
had a score of 2). The median score was 0 for each molec-
ular subgroup of GIST indicating low or absent expres-
sion of SSTR2 in the tumour tissue in all GIST tumours 
reviewed. No significant difference in the mean SSTR2 
expression score was demonstrated between molecular 
sub-groups of GIST (p = 0.1) (Fig. 2).
In vivo analysis of SSTR2 expression using [68 Ga]
Ga‑DOTATATE PET/CT imaging
High-quality  [68  Ga]Ga-DOTATATE PET/CT imag-
ing was obtained for all twelve patients included in this 
study. Imaging findings are summarised in Table  2. The 
liver was the most common site of wtGIST metastases in 
this series (11/12 cases, 91.6%). Measured SUVmax val-
ues of identified wtGIST metastases were highest in liver 
lesions due to high normal background. The mean size of 
the liver lesions from which SUVmax was 4.6 cm (range 
2.1 to 11  cm). The average SUV max for the most avid 
GIST lesion (one lesion per patient) was 6 (range 2–13), 
and the average lesion to liver ratio for a presumed GIST 
lesion was 0.7 (range 0.2 to 2). In most instances (8/12 
cases, 75%), metastases showed lower uptake than back-
ground liver (lesion to liver uptake ratio < 1) and  [68 Ga]
Ga-DOTATATE PET/CT imaging was reported as nega-
tive for high SSTR expression.
In four cases, lesions showed  [68  Ga]Ga-DOTA-
TATE uptake which was equal to or above that of 
background liver. In one case (case 012), the medias-
tinal mass suspicious for a metastatic recurrence of 
a previous wtGIST was subsequently confirmed as a 
mediastinal paraganglioma explaining the high  [68 Ga]
Ga-DOTATATE uptake in this lesion. Similarly for 
case 002, where several liver lesions showed uptake 
slightly higher than liver, this patient had a synchro-
nous carotid paraganglioma, and therefore, we cannot 
be certain that the liver metastases were all related to 
the wtGIST and not the co-existing paraganglioma as 
repeat biopsy was not performed and the patient is 
now deceased (Fig.  3). Heterogeneous tracer uptake 
Fig. 1 Images a–e demonstrates negative SSTR2 IHC for cases 005, 006, 007, 009 and aTK mutant GIST case (scores 1, 0, 1, 1 and 2, respectively). 
Figure F shows SSTR2 immunopositivity in a well-differentiated pancreatic neuroendocrine tumour used as a control (score 3)
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was demonstrated for two cases; case 003, in whom 
very few of the numerous liver lesions and a left gas-
tric node demonstrated uptake slightly higher than 
liver; case 009, where a few peritoneal nodules showed 
 [68  Ga]Ga-DOTATATE uptake comparable to liver, 
but multiple disease deposits showing no measur-
able uptake were documented in liver and abdomi-
nal nodes. Of note, anatomical imaging did not show 
significant necrosis and/or cystic features in any of 
the patients/lesions analysed to justify the low tracer 
uptake.
A negative or equivocal scan report for 11/12 
patients with metastatic wtGIST correlated with the 
low or absent expression of SSTR2 ex  vivo (Table  2). 
High  [68 Ga]Ga-DOTATATE avidity (> 2 times normal 
liver) was only noted in the synchronous or metachro-
nous PPGL lesions from case 2 and 12 (Fig. 4).
Discussion
To our knowledge, this is the first study to investigate 
the clinical utility of  [68  Ga]Ga-DOTATATE PET/CT in 
patients with wtGIST. In this study, SSTR2 expression 
was demonstrated to be low or absent for each of the 11 
cases of metastatic wtGIST analysed using  [68  Ga]Ga-
DOTATATE PET/CT and in tumour samples from 8/12 
patients using SSTR2 IHC. Notably, SSTR2 expression 
was also found to be low or absent in an additional 46 
tumour samples, including 23 TK-mutant GIST and an 
additional 23 wtGIST samples. A previous study inves-
tigating the expression of SSTR1-5 in TK-mutant GIST 
demonstrated expression of SSTR1-5 using both quan-
titative real-time polymerase chain reaction (qPCR) and 
IHC. In this earlier study, the expression of SSTR2 was 
lower than other SSTR subtypes and no wtGISTs were 
included in the analysis [16]. Zhao et  al. investigated 
SSTR1-5 expression in GIST using qPCR and IHC in 
Fig. 2 Panel A shows an axial fused  [18F]FDG PET/CT image of the liver with a maximum intensity projection (MIP) image demonstrating highly 
FDG-avid liver and nodal metastases in case 001. Panel B shows the corresponding (case 001) trans-axial fused image of the  [68 Ga]Ga-DOTATATE 
PET/CT and MIP image demonstrating low tracer uptake in the liver metastases (SUVmax 3) compared to background liver. Panel C, fused transaxial 
 [68 Ga]Ga-DOTATATE PET/CT image and corresponding MIP image showing non-avid liver metastases in case 010 (SUVmax 2.5). Panel D shows 
negative SSTR2 expression of a liver metastasis on IHC for case 010
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Fig. 3 Case 002. Panel A, transaxial fused  [18F]FDG PET/CT image of the liver and MIP image demonstrating FDG-avid liver, peritoneal and nodal 
metastases as well as a synchronous left sided carotid paraganglioma (small arrow). Panel B,  [68 Ga]Ga-DOTATATE PET/CT MIP image, demonstrating 
that few liver metastases show uptake higher than background liver (SUVmax 13, large arrow, vs 6.5 for background liver). It should be noted that 
not all liver lesions were biopsied so it remains unclear if all liver lesions were metastatic wtGIST deposits or if the carotid paraganglioma was also 
metastatic to the liver. The left sided carotid paraganglioma shows very intense uptake of the somatostatin analogue (SUVmax 60, small arrow). 
Panel C, negative SSTR2 expression on IHC in a biopsied dSDH wtGIST liver metastasis from case 002
Fig. 4 Case 012. Panel A,  [18F]FDG PET/CT MIP image and fused transaxial views showing a highly avid mediastinal mass and low-level uptake of 
an adjacent lymph node (C). This imaging was performed as part of surveillance for disease recurrence given a background of a resected wild-type 
GIST, and the mediastinal mass was a presumed recurrence of this earlier tumour. Panel B, 68 Ga-DOTATATE PET/CT, same views as above. Very 
intense uptake in the mediastinal mass (SUVmax 45) and adjacent lymph node (SUVmax 40). This patient had normal plasma metanephrine and 
3-methoxytyramine values on biochemical testing. Biopsy confirmed a non-secreting mediastinal dSDH paraganglioma case 012
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approximately 500 tumour samples and high expression 
levels of both SSTR1 and SSTR2 were noted; however, 
details regarding the molecular classification of the GIST 
samples were not provided [15]. While the additional 
anecdotal evidence from imaging studies [17, 18] encour-
aged us to pursue the possibility of a SSTR-2 targeting 
theragnostic strategy in this setting, the data obtained 
indicate that, at least in the case of wtGIST, this approach 
is not viable.
Alternative molecular targets are being investigated for 
radionuclide-based theranostics in GIST such as the gas-
trin releasing peptide/bombesin receptor (GRPR). PET 
imaging with a 68  Ga-labelled GRPR agonist identified 
lesions in 7/17 patients with GIST [25]. More recently, 
a 68 Ga-labelled GRPR antagonist (NeoBomb1) has been 
shown to have high selective binding in GIST derived cell 
lines [26]. These findings have led to a small phase 1/2a 
study assessing the safety and efficacy of this ligand for 
PET imaging of oligometastatic GIST [27], with the aim 
of developing a theranostic pathway based on this target-
ing strategy.
One indication for  [68  Ga]Ga-DOTATATE PET/CT is 
to confirm the diagnosis in patients with anatomic lesions 
that are suspicious for NET on conventional imaging 
[28]. The ability to utilise  [68  Ga]Ga-DOTATATE PET/
CT imaging as a virtual biopsy for NET is dependent on a 
good knowledge of the physiological uptake of  [68 Ga]Ga-
DOTATATE in normal tissue and recognising possibility 
of high tracer uptake in non-neuroendocrine tumours 
[29]. A previous case study using  [68 Ga]Ga-DOTATATE 
PET/CT imaging in a patient with a suspected meta-
static dSDH wtGIST demonstrated high SSTR2 tumour 
expression; however, this case had a synchronous para-
pharyngeal paraganglioma and the authors of this study 
rightfully acknowledged that the metastatic lesions iden-
tified on  [68  Ga]Ga-DOTATATE PET/CT imaging may 
relate to the PPGL rather than wtGIST [18].
The conventional radiological measurement of tumour 
response including uni- or bidimensional changes 
in tumour size (response evaluation criteria in solid 
tumours, RECIST) is routinely applied in clinical practice 
for both GIST and wtGIST using CT or MRI. The benefit 
of evaluating metabolic response using  [18F]FDG PET/
CT is well demonstrated in KIT- or PDGFRA- mutated 
GIST tumours following treatment with the tyrosine 
kinase inhibitor; imatinib, [30] as mesenchymal tumours 
such as GIST rarely demonstrate a reduction in size 
despite therapeutic response. As the majority of wtGIST 
are SDH-deficient, these tumours exhibit upregulation of 
hexokinase receptors [31] and increased 18F-FDG uptake, 
and therefore, it is likely that this may mitigate any ben-
efit of 18F-FDG PET/CT in determining therapeutic 
response to tyrosine kinase inhibitors in wtGIST, but 
18F-FDG PET/CT remains a sensitive imaging modality 
for SDH deficient tumours [31] although it lacks the abil-
ity to differentiate between tumour types (e.g. PGL ver-
sus wtGIST).
Patients with dSDH wtGIST due to a germline vari-
ant in SDHx or SDHC epimutations are at risk of mul-
tiple tumours including multifocal PPGL, pulmonary 
chondroma and renal cell carcinoma. In this study, case 
002 had a metastatic dSDH wtGIST and a synchronous 
carotid paraganglioma. Notably, a few liver metasta-
ses demonstrated uptake higher than background liver 
(SUVmax 13) and the carotid paraganglioma demon-
strated very high somatostatin tracer uptake. It is worth 
noting that not all liver lesions were biopsied, and there-
fore, it is not certain if some of the liver lesions may have 
been metastatic deposits from the carotid paraganglioma 
rather than the dSDH wtGIST. Furthermore, patients 
with cSDH wtGIST associated with NF1 are also predis-
posed to the development of multiple tumours over their 
lifetime. Notably, the location of PPGL in patients with 
germline SDHx mutations or SDHC epimutations can 
be anywhere from the skull base to the pelvis and dSDH 
PPGL also have a high malignant potential [32], increas-
ing the risk for synchronous malignant primary tumours 
in one individual. Therefore, as  [18F]FDG PET/CT lacks 
the ability to differentiate between at risk tumour types 
in patients with SDHx mutations, there is an unmet need 
for sensitive and specific imaging modalities which are 
able to distinguish PPGL from wtGIST in this patient 
population in order to avoid multiple biopsies and inform 
appropriate management with proper use of molecular 
imaging.
In this study,  [68  Ga]Ga-DOTATATE PET/CT imag-
ing was negative for nine patients and equivocal for two 
patients with metastatic wtGIST. However, the uptake 
level in a synchronous carotid PPGL (SUVmax 60) in case 
002 and a metachronous mediastinal PPGL in case 012 
(SUVmax 45) was almost ten-fold higher than liver refer-
ence in these individuals and 9–tenfold higher than the 
average uptake seen in metastases of 11 cases of wtGIST 
(mean SUVmax 6). These results suggest that  [68 Ga]Ga-
DOTATATE PET/CT imaging may have specific utility 
for differentiating PPGL from wtGIST in clinical practice 
in patients with a genetic predisposition to develop both 
tumour types.
Conclusions
Our results address conflicting reports in the literature 
on the role of SSTR2 in wtGIST and indicate that this 
receptor system is not a viable diagnostic or therapeutic 
target. We show that  [68  Ga]Ga-DOTATATE PET/CT 
may have an important diagnostic role in identifying and 
differentiating PPGL lesions from metastatic wtGIST in 
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patients carrying genetic mutations predisposing to both 
conditions.
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